疏肝安神法防治失眠与多巴胺受体途径的相关性研究

Study on the Relationship between the Prevention of Insomnia and the Dopamine Receptor Pathway by Shugan Anshen Method

摘要: 目的：观察疏肝安神类中药复方松郁安神方防治失眠的作用与多巴胺受体的相关性。方法：利用失眠大鼠模型，造模成功后分别给予松郁安神方(SYF)、多巴胺受体激动剂pergolide、多巴胺受体拮抗剂spiperone以及联合用药1周。治疗结束后通过酶联免疫吸附测定(Elisa)方法检测大鼠脑组织和血浆中神经递质多巴胺(DA)的含量。运用Western Blotting实验检测脑组织多巴胺受体D2DR蛋白表达水平。结果：同对照组相比较，模型组和pergolide组大鼠脑组织和血浆中DA含量显著升高(P < 0.01)，脑组织中D2DR蛋白表达水平同样显著上调(P < 0.01)。而SYF组、spiperone组则使得大鼠脑组织和血浆中DA含量以及D2DR蛋白表达水平均被显著性的降低(P < 0.01)，联合用药组也呈现了同样的结果。SYF组 + pergolide组同pergolide组比较，大鼠脑组织和血浆中DA含量以及D2DR蛋白表达水平均被显著性的下调(P < 0.01)。结论：肝郁型失眠的发生机制同多巴胺受体激动剂作用相似，松郁安神方能够抑制多巴胺受体激动剂诱导的D2DR蛋白表达和DA的释放，与多巴胺受体拮抗剂作用相似，表明了疏肝安神法防治失眠的作用可能与多巴胺受体途径相关。

Abstract: Objective: To observe the correlation between shugan anshen traditional Chinese medicine compound songyu anshen prescription and dopamine receptor in preventing insomnia. Methods: Insomnia model of rat was used. After successful modeling, SYF, dopamine receptor agonist pergolide, dopamine receptor antagonist spiperone, and drug combination were given for one week. At the end of the treatment, the contents of the neurotransmitter dopamine (DA) in rat brain tissue and plasma were determined by enzyme-linked immunosorbent assay (Elisa). Western Blotting assay was used to detect the expression level of dopamine receptor D2DR protein in brain tissue. Results: Compared with the control group, DA content in brain tissue and plasma of rats in the model group and pergolide group was significantly increased (P < 0.01), and D2DR protein expression level in brain tissue was also significantly increased (P < 0.01). However, in SYF + spiperone group, DA content and D2DR protein expression level in brain tissue and plasma of rats were significantly reduced (P < 0.01), and the same results were also observed in the combination group. Compared with pergolide group, DA content and D2DR protein expression level in brain tissue and plasma of SYF + pergolide group were significantly down-regulated (P < 0.01). Conclusion: The pathogenesis of liver-depression insomnia is similar to the action of dopamine receptor agonist. Songyu anshen prescription can inhibit the expression of D2DR protein and the release of DA induced by dopamine receptor agonist, and has the similar action with dopamine receptor antagonist, indicating that the action of shugan anshen method in preventing insomnia may be related to the dopamine receptor pathway.